Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

1

TransCon PTH demonstrated sustained efficacy in adults with hypoparathyroidism, with 81% achieving normal serum calcium by week 52.
2

95% of participants on TransCon PTH achieved independence from conventional therapy, indicating significant clinical improvement.
3

Patient-reported outcomes showed sustained enhancements in quality of life, physical functioning, and overall well-being after 52 weeks.
4

Mean 24-hour urine calcium excretion significantly decreased from baseline, indicating improved calcium regulation.
5

TransCon PTH was well-tolerated, with most adverse events being mild or moderate, and none leading to trial discontinuation.

The Journal Of Clinical Endocrinology & Metabolism

by Bart L Clarke, Aliya A Khan, Mishaela R Rubin, Peter Schwarz, Tamara Vokes, Dolores M Shoback, Claudia Gagnon, Andrea Palermo, Lisa G Abbott, Lorenz C Hofbauer, Lynn Kohlmeier, Filomena Cetani, Susanne Pihl, Xuebei An, Alden R Smith, Bryant Lai, Jenny Ukena, Christopher T Sibley, Aimee D Shu, Lars Rejnmark
October 8, 2024

1